Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from MRK

5 Defensive Stocks to Own for Consistent Dividends and Stable Earnings

Concerns over the Russia-Ukraine war and high inflation have significantly affected the global equity markets lately. As the stock market is expected to remain highly volatile in the coming weeks, it could be wise to bet on defensive stocks Walmart (WMT), Novartis (NVS), Merck & Co. (MRK), GlaxoSmithKline (GSK), and…

3 Wide-Moat Stocks to Withstand a Market Downturn: Microsoft, Merck, and Blackbaud

3 Wide-Moat Stocks to Withstand a Market Downturn: Microsoft, Merck, and Blackbaud

The major stock market indices suffered a sell-off as the news of Russia’s military action in Ukraine broke. But because wide-moat companies generally fare well in challenging times like these, we believe VanEck Vectors Morningstar Wide Moat ETF’s (MOAT) holdings Microsoft (MSFT), Merck & Co. (MRK), and Blackbaud (BLKB) might…

This Is What Whales Are Betting On Merck & Co

This Is What Whales Are Betting On Merck & Co

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Merck & Co Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Stabilize Your Portfolio with These 5 High-Quality Stocks

The stock indices are down, heading for a second straight losing week on investor concerns about geopolitical tensions and the Fed’s actions. And the market is expected to remain volatile in the near term. Hence, we think high-quality stocks Merck & Co. (MRK), Archer-Daniels-Midland (ADM), Baxter (BAX), McKesson (MCK), and…

See Why Did FDA Update Merck's COVID-19 Pill Emergency Use Authorization

The FDA has revised the Emergency Use Authorization (EUA) for Merck & Co Inc's (NYSE: MRK) COVID-19 pill mo

South Africa Authorizes Merck's COVID-19 Antiviral Pill, But Government Not Buying: Reuters

South Africa's government said it was not planning to buy Merck & Co Inc's (NYSE: MRK) COVID-19 treatment pill molnupiravir for cost reasons, despite the drug gaining approval in the country.

inkl

Read news from The Economist, FT, and more,
with one subscription

Merck Inks Oncology, Neurology Drug Discovery Pact With British Biotech, Curve Therapeutics

Merck Inks Oncology, Neurology Drug Discovery Pact With British Biotech, Curve Therapeutics

Privately-held Curve Therapeutics has inked a contract with Merck & Co Inc (NYSE: MRK) to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications.

Merck & Co Whale Trades For February 10

Merck & Co Whale Trades For February 10

Someone with a lot of money to spend has taken a bullish stance on Merck & Co (NYSE:MRK). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales

Merck Clocked $950M Sales In Q4 From COVID-19 Treatment, Issues FY22 Sales

Merck & Co Inc's (NYSE: MRK) Q4 sales re

Recap: Merck & Co Q4 Earnings

Recap: Merck & Co Q4 Earnings

Merck & Co (NYSE:MRK) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Preview: Merck & Co's Earnings

Preview: Merck & Co's Earnings

Merck & Co (NYSE:MRK) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Merck & Co will likely report an Earnings Per Share (EPS) of $1.53.

Analyst Ratings For Merck & Co

Analyst Ratings For Merck & Co

Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:

Merck's COVID-19 Pill works Against Omicron, Lab Studies Show

Merck's COVID-19 Pill works Against Omicron, Lab Studies Show

Merck & Co Inc (NYSE: MRK) and its partner Ridgeback Biotherapeutics said six lab studies showed their investigational oral COVID-19 drug molnupiravir was

Get all your
news in one place.

100’s of premium titles.
One news app.

3 Top Dow Jones Stocks to Safeguard Your Portfolio

The market remains turbulent amid worries related to rising inflation, looming interest rate hikes, and geopolitical tensions. However, the Dow Jones Industrial Average is down the least out of the three major indices. Investing in hot Dow stock Merck (MRK), Amgen (AMGN), and Walgreens (WBA) could help safeguard your portfolio…

Britain To Test Merck - Ridgeback Biotherapeutics' COVID-19 Antiviral Pill In Hospitalized Patients

British scientists will start testing Merck & Co Inc (NYSE: MRK) and Ridgeback Biotherapeutics' COVID-19 antiviral pill molnupiravir as a possible treatment for patients hospitalized with COVID-19,

Merck Scores Win In Insurance Battle Over Cyberattack - Bloomberg Report

Bloomberg reported that Merck & Co Inc (NYSE: MRK) has won a long-running legal battle to force its insurer to cover the costs of damages caused by the NotPetya' ransomware' attacks.

Merck's Keytruda Manages To Cross The Finish Line In Liver Cancer Confirmatory Trial

Merck & Co Inc (NYSE: MRK) has

Get all your
news in one place.

100’s of premium titles.
One news app.

Organisations

US Federal Reserve

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

253,443 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play